B5: the scheduled dose of idursulfase was 24mg in 100ml of saline solution.H4: device manufactured on september 2021.H10: the actual device was not available; however, photographs of the sample was provided for evaluation. visual inspection of the photographs was performed using the naked eye which revealed a detachment at level of drip chamber.The reported condition was verified on the photograph. the cause of the condition could not be determined. additionally, a visual inspection was performed on the retention samples with no issues noted.The retention samples were gravity tested, then leak tested under water via a calibrated provaset with no leak or issues observed.The reported condition was not verified on the retention samples.A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.Should additional relevant information become available, a supplemental report will be submitted.
|